A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & EXTEND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (DIAGRID)

Published: 31-01-2022
Last updated: 05-04-2024

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the PDS with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per a treat-and-extend regimen (aflibercept...

Ethical review	Approved WMO
Status	Will not start
Health condition type	Retina, choroid and vitreous haemorrhages and vascular disorders
Study type	Interventional

Summary

ID

NL-OMON52092

Source
ToetsingOnline

Brief title
MR42410 Diagrid

Condition

- Retina, choroid and vitreous haemorrhages and vascular disorders

Synonym
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, Wet AMD

Research involving
Human

Sponsors and support

Primary sponsor: Roche Nederland B.V.
Source(s) of monetary or material Support: Roche Nederland B.V.

Intervention

Keyword: Neovascular Age-related macular degenarion, Phase IIIb, Port delivery system, Ranibizumab

Outcome measures

Primary outcome

The primary objective for this study is to evaluate the effectiveness of PDS

Q36W compared with aflibercept T&E through the co-primary endpoints:

- Change from baseline in BCVA score averaged over Weeks 76 (or 78) and 80, as

assessed using the ETDRS visual acuity chart at a starting distance of 4 meters

- Treatment burden as assessed by the treatment frequency up to Week 80

Secondary outcome

The secondary objective for this study is to evaluate the effectiveness of PDS

Q36W compared with aflibercept T&E on the basis of the following endpoints:

- Proportion of subjects with BCVA score of 69 letters (approximate 20/40

Snellen equivalent) or better averaged over Weeks 76 (or 78) and 80

- Proportion of subjects with BCVA score of 38 letters (approximate 20/200

Snellen equivalent) or worse averaged over Weeks 76 (or 78) and 80

See protocol section 2.1.2 for all secondary objectives

Study description

Background summary

Neovascular age-related macular degeneration (nAMD), also known as wet AMD or choroidal neovascularization (CNV) secondary to AMD, is a form of advanced AMD that causes rapid and severe visual loss, and remains a leading cause of visual impairment.
The PDS is an innovative, investigational, intraocular drug delivery system that allows clinicians to use ranibizumab with a continuous drug delivery profile. It consists of investigational devices, including an intraocular implant, four ancillary devices (insertion tool assembly, initial fill needle, refill needle, and explant tool), and a customized formulation of ranibizumab tailored for continuous delivery.

Study objective

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the PDS with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per a treat-and-extend regimen (aflibercept T&E) in subjects with nAMD.

Study design

Study MR42410 is a Phase IIIb, multicenter, randomized, two-arm, visual assessor-masked trial designed to evaluate the effectiveness and safety of PDS Q36W compared with aflibercept T&E in subjects with nAMD.

Intervention

One group will receive the implant with ranibizumab and refills every 36 weeks, the other group will receive aflibercept with an treat-and-extend regimen of 4/8/12 weeks

Study burden and risks

Patients in the implant arm will need surgery and possible surgery to remove the implant. These surgeries have risks. Patients need to come to site for checks every 4/8/12 weeks.
Patients in comparator arm will follow a similar regime as they would have in standard of care. Visits will be longer as more assessments are done that in standard care.

All patients will have 3 moments where there will be interviewer-administered questionnaires about their visual function and treatment preference.

At randomisation and at week 80 an aqueous humor sample will be taken.

Contacts

Public
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL
Scientific
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

General inclusion criteria
•Age =>50 years, at time of signing Informed Consent Form
•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures during the treatment period and for at least 3 months after the final intravitreal injection of ranibizumab or aflibercept, or 1 year after the last implant refill of ranibizumab

Ocular Inclusion Criteria
•Initial diagnosis of nAMD within 9 months prior to the screening visit
•Previous treatment with at least three anti- vascular endothelial growth factor (VEGF) intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit
•Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis, as evidenced by the following: a) Overall decrease in nAMD disease activity detected on SD-OCT, as assessed by the investigator and confirmed by the central reading center and b) Stable or improved BCVA at randomization
See section 4.1.1 of the protocol for all inclusion criteria

Exclusion criteria

Study Eye
•History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
•Subretinal hemorrhage that involves the center of the fovea
•Subfoveal fibrosis or subfoveal atrophy

Either Eye
•History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the ranibizumab or aflibercept injections, study-related procedure preparations, dilating drops, or any of the anesthetic and antimicrobial preparations used by a subject
•Any contraindication to aflibercept
•Prior participation in a clinical trial involving any anti-VEGF drugs within 6 mths prior to the randomization visit
•CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia
•CNV masquerading lesions

See section 4.1.2 of the protocol for all exclusion criteria

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Will not start
Enrollment:	15
Type:	Anticipated

Medical products/devices used

Generic name:	Port Delivery System (PDS)
Registration:	No
Product type:	Medicine
Brand name:	EYLEA
Generic name:	Aflibercept
Registration:	Yes - NL intended use
Product type:	Medicine
Brand name:	Susvimo
Generic name:	RANIBIZUMAB

Ethics review

Approved WMO

Date:	31-01-2022
Application type:	First submission

Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	22-03-2022
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	11-06-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	10-08-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	12-09-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	28-09-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	25-10-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO Date:	03-11-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	

Date:	13-10-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2021-003226-71-NL
ClinicalTrials.gov	NCT05126966
CCMO	NL78857.100.21